Prelude Therapeutics (PRLD) to Release Earnings on Monday

Prelude Therapeutics (NASDAQ:PRLD) will likely be announcing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Prelude Therapeutics to post earnings of ($0.33) per share and revenue of $20.50 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 1:30 PM ET.

Prelude Therapeutics Trading Up 3.5%

Shares of PRLD opened at $3.23 on Friday. The company has a market cap of $203.07 million, a price-to-earnings ratio of -2.20 and a beta of 0.79. The business’s fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $1.80. Prelude Therapeutics has a 12 month low of $0.61 and a 12 month high of $4.22.

Institutional Trading of Prelude Therapeutics

A number of hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in Prelude Therapeutics by 170.7% in the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after acquiring an additional 21,330 shares during the period. Marshall Wace LLP bought a new position in shares of Prelude Therapeutics in the 2nd quarter worth approximately $34,000. XTX Topco Ltd lifted its stake in shares of Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock worth $34,000 after purchasing an additional 17,873 shares during the period. Shay Capital LLC purchased a new position in shares of Prelude Therapeutics in the second quarter worth approximately $61,000. Finally, Jane Street Group LLC bought a new position in Prelude Therapeutics in the 2nd quarter worth $74,000. Hedge funds and other institutional investors own 79.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PRLD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Prelude Therapeutics currently has an average rating of “Hold” and a consensus price target of $4.00.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.